Alzheimer Disease (AD)AUMASMARTNCT07826975
Assessment of Changes in Autonomy Through Analysis of Smartphone Usage Data in Patients With Alzheimer's Disease
An observational study of Alzheimer Disease (AD), run by Poitiers University Hospital.
Trial summary
Alzheimer's disease is the leading cause of dementia worldwide. The first cognitive function to be affected is memory. As the disease progresses, other cognitive systems are affected, leading to a gradual loss of independence for the patient. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Alzheimer Disease (AD)
- What is being tested?
- Data collection, Neuropsychological assesment and Autonomy questionnaire
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Sep 2026to Mar 2030
- How long will I take part?
- 18 Months
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients receiving routine care at a memory resource and research center for Alzheimer's disease who own an Android smartphone.
Who may be able to join
- Age ≥ 60 years
- Patient consulting on routine care at a memory resource and research center for Alzheimer's disease defined by cognitive memory complaints from the patient or their family and friends, evidence of impaired verbal episodic memory storage in FCSRT defined by a sum of FR values less than 17/48 and a sum of CR values less than 40/48 compared to the patient's age and socio-cultural level and no criteria on other neuropsychological tests, progressive decline over at least 6 months affecting independence, and if a brain MRI, a lumbar puncture, and/or an 18FDG PET scan were performed as part of the patient's routine care, the results must be consistent with a diagnosis of MA.
- Patient with a smartphone for their exclusive use that is compatible with the installation of the IMASMART application on Android
- No sensory impairment (vision or hearing impairment) that could compromise the use of a smartphone
- Absence of major anxiety-depressive disorder defined by a HAD score > 16
- Patient an caregiver not objecting to participating in the study
Who cannot join
- Inability to perform the Mini-Mental State Examination or score < 17
- Other neurodegenerative disorders
- Severe, unstable psychiatric disorders
- Terminal phase of a severe illness
- Other conditions that may compromise the use of a smartphone
- Patients with an iPhone
Show all 10Show fewer
- MRI evidence of a lesion that may contribute to cognitive impairment (stroke, tumors, etc.)
- Refusal to install the application
- People residing in a residential care for senior or any other medical facility
- Individuals benefiting from enhanced protection, namely individuals deprived of their liberty by judicial or administrative decision, adults under legal protection, and finally, patients in emergency situations.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Alzheimer's disease is the leading cause of dementia worldwide. The first cognitive function to be affected is memory. As the disease progresses, other cognitive systems are affected, leading to a gradual loss of independence for the patient. This loss of independence is at the heart of the psychosocial and medico-economic challenges posed by Alzheimer's disease. Functional independence refers to the patient's ability to perform activities of daily living. The evolution of autonomy varies significantly from one individual to another, and a specific, personalized assessment is necessary in order to offer appropriate care and services. There is a link between patient autonomy and psycho-behavioral disorders. Early identification of loss of autonomy in connection with psycho-behavioral disorders would allow specific treatment to be put in place.
The study hypothesis is that there is a link between changes in smartphone data and changes in the independence of patients with AD.
- Conditions
- Alzheimer Disease (AD)
- Being tested
- Data collection, Neuropsychological assesment, Autonomy questionnaire
- Medical subject headings
- Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Data collectionOther
Collection of Android smartphone usage
Neuropsychological assesmentOther
MMSE, FCSRT, FAB, TMT, verbal fluency test, Rey figure, BBEP, langage assesments and HAD scale
Autonomy questionnaireOther
IADL Amsterdam assessed by the caregiver
| Study group | Role | What they receive |
|---|---|---|
| Alzheimer's patients | Not described Receives: Other: Data collection; Other: Neuropsychological assesment; Other: Autonomy questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of changes in smartphone usage data and battery life collected at 0 and 18 months
To measure the relationship between variations in smartphone usage data-represented as a single parameter created through a mathematical combination-and variations in the Amsterdam IADL questionnaire between 0 and 18 months.
Measured: From enrollment to the end of participation at 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study startSep 2026 (estimated)
- Primary completionMar 2030 (estimated)
- Study completionMar 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer Disease (AD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 18 Months
Sponsor and investigators
- Lead sponsor
- Poitiers University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Céline ABONNEAU, Study chair, Poitiers University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07826975
- Sponsor's protocol ID
- 2025-A01157-42
- Acronym
- AUMASMART
- Status last verified
- Aug 2026
- First submitted
- 10 Apr 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided